TransMedics Group (NASDAQ:TMDX) Given New $175.00 Price Target at Oppenheimer

TransMedics Group (NASDAQ:TMDX) had its target price increased by investment analysts at Oppenheimer from $150.00 to $175.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 30.18% from the company’s previous close.

Several other equities research analysts have also weighed in on TMDX. Piper Sandler lifted their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Morgan Stanley lifted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Finally, Needham & Company LLC increased their target price on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $150.67.

TransMedics Group Stock Performance

NASDAQ:TMDX traded down $3.35 during trading hours on Wednesday, reaching $134.43. The stock had a trading volume of 1,648,105 shares, compared to its average volume of 751,713. The stock has a market cap of $4.59 billion, a P/E ratio of 54.15 and a beta of 2.06. The stock has a 50 day simple moving average of $132.98 and a 200 day simple moving average of $126.22. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group has a 12-month low of $62.07 and a 12-month high of $156.00.

Insiders Place Their Bets

In other news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Weill sold 5,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares in the company, valued at $1,682,257.76. This trade represents a 29.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

A number of large investors have recently modified their holdings of TMDX. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC purchased a new position in TransMedics Group in the 3rd quarter worth approximately $28,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the 3rd quarter worth approximately $29,000. Optiver Holding B.V. increased its holdings in shares of TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the last quarter. Finally, Allworth Financial LP raised its position in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q4 results showed a large beat: EPS of $2.62 vs. consensus $0.41 and revenue of $160.8M (+32% YoY). Management provided materials and slides alongside the release. MarketBeat: Earnings Report
• Positive Sentiment: Company issued FY2026 revenue guidance of roughly $727M–$757M (vs. consensus ~$722.8M), signaling continued top‑line growth for the year. PR Newswire: Financial Results & Guidance
• Positive Sentiment: TransMedics outlined a 20–25% revenue growth target for 2026 and highlighted progress on OCS programs and European expansion—key operational drivers for future unit growth. Seeking Alpha: 2026 Revenue Target & OCS Programs
• Positive Sentiment: Analyst upgrades: Needham raised its price target to $174 (Buy) and Piper Sandler lifted its target to $160 (Overweight), reflecting increased upside expectations. Benzinga: Needham Price Target Benzinga: Piper Sandler Price Target
• Positive Sentiment: Market reaction coverage noted a surge after the earnings beat and solid guidance, confirming short‑term bullish sentiment among some traders. Investing.com: Market Reaction
• Neutral Sentiment: Detailed analyses and the full earnings‑call transcript are available for investors who want to dig into unit economics, margin drivers and the cadence of OCS commercialization. Seeking Alpha: Earnings Call Transcript
• Neutral Sentiment: Analyst notes and metric comparisons (Zacks) break down how key metrics stacked up vs. estimates—useful for modeling but not new headline news. Zacks: Key Metrics vs Estimates

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.